<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5977">
  <stage>Registered</stage>
  <submitdate>13/02/2015</submitdate>
  <approvaldate>13/02/2015</approvaldate>
  <nctid>NCT02384460</nctid>
  <trial_identification>
    <studytitle>ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa</studytitle>
    <scientifictitle>A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-002288-14</secondaryid>
    <secondaryid>SD-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epidermolysis Bullosa</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SD-101-6.0 cream
Treatment: drugs - SD-101-0.0 cream

Experimental: SD-101-6.0 cream - SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days

Placebo Comparator: SD-101-0.0 cream - SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days


Treatment: drugs: SD-101-6.0 cream
applied topically once a day for 90 days

Treatment: drugs: SD-101-0.0 cream
applied topically once a day for 90 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to complete target wound closure</outcome>
      <timepoint>Within 3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The proportion of patients experiencing complete closure of their target wound.</outcome>
      <timepoint>Within 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients experiencing complete closure of their target wound.</outcome>
      <timepoint>Within 2 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients experiencing complete closure of their target wound.</outcome>
      <timepoint>Within 1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in lesional skin - Based on BSAI at month 3, compared to baseline</outcome>
      <timepoint>Month 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change of Total Body Wound Burden based on BSAI - Assessed at month 3; compared to baseline</outcome>
      <timepoint>Month 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in itching - Assessed at Day 7, compared to baseline</outcome>
      <timepoint>Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in pain - Assessed at Day 7, compared to baseline</outcome>
      <timepoint>Day 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed Consent form signed by the patient or patient's legal representative; if the
             patient is under the age of 18 but capable of providing assent, signed assent from the
             patient.

          -  Patient (or caretaker) must be willing to comply with all protocol requirements.

          -  Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.

          -  Patient must have 1 target wound within a prespecified size range at study entry

          -  Patients 1 month and older.

          -  Target wound must of at least a certain age</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Month</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who do not meet the entry criteria outlined above.

          -  Selected target wound cannot have clinical evidence of local infection.

          -  Use of any investigational drug within the 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within the 30 days before enrollment.
             (Inhaled steroids and ophthalmic drops containing steroids are allowed)

          -  Use of systemic antibiotics within the 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated lesions.

          -  Pregnancy or breastfeeding during the study. (A urine pregnancy test will be performed
             at screening and every 30 days until the final visit for female patients of
             childbearing potential)

          -  Females of childbearing potential who are not abstinent and not practicing a medically
             acceptable method of contraception.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Premier Specialists Pty Ltd. - Kogarah</hospital>
    <hospital>The Royal Melbourne Hospital - Parkville</hospital>
    <hospital>The Royal Children's Hospital - Parkville</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Koszykowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Scioderm, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Amicus Therapeutics, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim is to assess the efficacy and safety of SD-101-6.0 cream versus SD-101-0.0 (placebo)
      in the treatment of patients with Epidermolysis Bullosa. Funding Source - FDA OOPD</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02384460</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>